InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.77%
)
US TECH 100
19,439.20
(
0.19%
)
Dow Jones
38,778.10
(
0.49%
)
Brent Oil
83.59
(
-0.37%
)
Bitcoin
65,416.32
(
-1.61%
)
Post# of 252233
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119861
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RVNCfan post# 249454

Friday, 10/20/2023 7:11:22 PM

Friday, October 20, 2023 7:11:22 PM

Post# of 252233

[AEON/RVNC]—Abbvie…started Phase-3 trial in Episodic Migraine so I thought it would be easy to meet the endpoint.

Clinical trials where the efficacy endpoint is subjective (i.e. how the patient feels rather than an empirical measurement) tend to have high failure rates even if the drug being tested has bona fide activity.

As a RVNC shareholder, I won’t object if RVNC opts to forgo Daxxify trials in such indications as migraine and depression.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up